MX2023002978A - Virus adenoasociado recombinante (raav) que codifica la union gap beta 2 (gjb2) y sus usos. - Google Patents

Virus adenoasociado recombinante (raav) que codifica la union gap beta 2 (gjb2) y sus usos.

Info

Publication number
MX2023002978A
MX2023002978A MX2023002978A MX2023002978A MX2023002978A MX 2023002978 A MX2023002978 A MX 2023002978A MX 2023002978 A MX2023002978 A MX 2023002978A MX 2023002978 A MX2023002978 A MX 2023002978A MX 2023002978 A MX2023002978 A MX 2023002978A
Authority
MX
Mexico
Prior art keywords
gjb2
raav
encoding
utr
nucleic acid
Prior art date
Application number
MX2023002978A
Other languages
English (en)
Spanish (es)
Inventor
David P Corey
Kevin T Booth
Cole W D Peters
Maryna V Ivanchenko
Michael E Greenberg
Sinisa Hrvatin
Mark Aurel Nagy
Eric C Griffith
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of MX2023002978A publication Critical patent/MX2023002978A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2023002978A 2020-09-14 2021-09-14 Virus adenoasociado recombinante (raav) que codifica la union gap beta 2 (gjb2) y sus usos. MX2023002978A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063078233P 2020-09-14 2020-09-14
US202163161619P 2021-03-16 2021-03-16
PCT/US2021/050205 WO2022056444A1 (en) 2020-09-14 2021-09-14 Recombinant adeno associated virus (raav) encoding gjb2 and uses thereof

Publications (1)

Publication Number Publication Date
MX2023002978A true MX2023002978A (es) 2023-06-01

Family

ID=80631939

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002978A MX2023002978A (es) 2020-09-14 2021-09-14 Virus adenoasociado recombinante (raav) que codifica la union gap beta 2 (gjb2) y sus usos.

Country Status (10)

Country Link
EP (1) EP4211151A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023541443A (cg-RX-API-DMAC7.html)
KR (1) KR20230069157A (cg-RX-API-DMAC7.html)
AU (1) AU2021339843A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023004605A2 (cg-RX-API-DMAC7.html)
CA (1) CA3191533A1 (cg-RX-API-DMAC7.html)
IL (1) IL301057A (cg-RX-API-DMAC7.html)
MX (1) MX2023002978A (cg-RX-API-DMAC7.html)
TW (1) TW202227476A (cg-RX-API-DMAC7.html)
WO (1) WO2022056444A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7713130B2 (ja) * 2019-09-30 2025-07-25 イーライ リリー アンド カンパニー 遺伝性難聴の処置のためのアデノ随伴ウイルス(aav)システム
WO2024011224A2 (en) * 2022-07-08 2024-01-11 The Trustees Of Columbia University In The City Of New York Regulatory element for cell type specific expression of genes in spinal motor neurons
EP4698555A1 (en) * 2023-04-18 2026-02-25 uniQure biopharma B.V. Novel neurotropic adeno-associated virus capsids with detargeting of peripheral organs
EP4713463A1 (en) * 2023-05-18 2026-03-25 Decibel Therapeutics, Inc. Compositions and methods for treating gjb2-related hearing loss

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1308458A1 (en) * 2001-10-30 2003-05-07 GenOdyssee New polynucleotides and polypeptides of the CX26 gene
WO2006009870A2 (en) * 2004-06-17 2006-01-26 Epigenomics Ag Compositions and methods for preventing carry-over contamination in nucleic acid amplification reactions
CN101389769A (zh) * 2005-12-28 2009-03-18 森托科尔公司 用于评价和治疗银屑病及相关疾病的标记与方法
WO2019200016A1 (en) * 2018-04-10 2019-10-17 President And Fellows Of Harvard College Aav vectors encoding clarin-1 or gjb2 and uses thereof
US12534739B2 (en) * 2018-10-11 2026-01-27 Decibel Therapeutics, Inc. AAV1 vectors and uses thereof for treatment of otic indications
CN113853437A (zh) * 2018-11-07 2021-12-28 阿库斯股份有限公司 腺相关病毒载体用于在内耳中的毛细胞和支持细胞中校正基因缺陷/表达蛋白质的用途
JP7713130B2 (ja) * 2019-09-30 2025-07-25 イーライ リリー アンド カンパニー 遺伝性難聴の処置のためのアデノ随伴ウイルス(aav)システム
CN116096900A (zh) * 2020-05-13 2023-05-09 阿库斯股份有限公司 用于治疗gjb2相关听力损失的组合物和方法
MX2023013394A (es) * 2021-05-13 2023-12-14 Akouos Inc Composiciones de suministro de terapia genica y metodos para tratar perdida auditiva.

Also Published As

Publication number Publication date
KR20230069157A (ko) 2023-05-18
WO2022056444A1 (en) 2022-03-17
EP4211151A4 (en) 2025-03-26
JP2023541443A (ja) 2023-10-02
IL301057A (en) 2023-05-01
TW202227476A (zh) 2022-07-16
AU2021339843A1 (en) 2023-04-06
BR112023004605A2 (pt) 2023-04-11
CA3191533A1 (en) 2022-03-17
EP4211151A1 (en) 2023-07-19

Similar Documents

Publication Publication Date Title
BR112023004605A2 (pt) Vírus adeno-associado recombinante (raav) codificando gjb2 e usos do mesmo
JP7814280B2 (ja) ヒト対象において非加齢性聴力障害を治療するための組成物および方法
Shibata et al. RNA interference prevents autosomal-dominant hearing loss
Hildebrand et al. Advances in molecular and cellular therapies for hearing loss
Prigione et al. HIF1 α modulates cell fate reprogramming through early glycolytic shift and upregulation of PDK1–3 and PKM2
Yoshimura et al. Targeted allele suppression prevents progressive hearing loss in the mature murine model of human TMC1 deafness
Das et al. Interferon-inducible protein IFI35 negatively regulates RIG-I antiviral signaling and supports vesicular stomatitis virus replication
WO2022032154A3 (en) Compositions for the delivery of payload molecules to airway epithelium
MX2023001538A (es) Composiciones y metodos para inhibir la expresion de lpa.
MX2019001493A (es) Agentes de iarn para infección causada por el virus de la hepatitis b.
CR20210444A (es) Composiciones y métodos para tratar distrofia cristalina de bietti
Schultz et al. Differentiation of neurons restricts Arbovirus replication and increases expression of the alpha isoform of IRF-7
Orimoto et al. Efficient immortalization of human dental pulp stem cells with expression of cell cycle regulators with the intact chromosomal condition
CL2021000798A1 (es) Composiciones útiles para el tratamiento de la gangliosidosis gm1.
Song et al. RBM39 alters phosphorylation of c-Jun and binds to viral RNA to promote PRRSV proliferation
WO2021231808A2 (en) Compositions and methods for treating gjb2-associated hearing loss
Aaron et al. Selection of viral capsids and promoters affects the efficacy of rescue of Tmprss3-deficient cochlea
PE20240240A1 (es) Composiciones de administracion de terapia genica y metodos para el tratamiento de la perdida auditiva
Taiber et al. Genetic therapies for hearing loss: Accomplishments and remaining challenges
Luo et al. A recombinant rabies virus carrying GFP between N and P affects viral transcription in vitro
WO2021021674A1 (en) Methods of treating hearing loss using a secreted target protein
BR112022023908A2 (pt) Composições de vírus adenoassociados para restauração da função do gene pah e métodos de uso das mesmas
MX2021003002A (es) Composicion para el tratamiento de enfermedades fibroticas, que comprende un compuesto de tioacetamida de benzhidrilo como ingrediente activo.
Ghimire et al. Toll-like receptor 7 (TLR7)-mediated antiviral response protects mice from lethal SARS-CoV-2 infection
Ukaji et al. AAV-mediated base editing restores cochlear gap junction in GJB2 dominant-negative mutation-associated syndromic hearing loss model